A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Lenalidomide
Related studies linked through entity extraction aliases.
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade
- Status
- COMPLETED
- Phase
- PHASE2
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Study of Grifola Frondosa (Maitake), Azacitidine, and Lenalidomide
- Status
- TERMINATED
- Phase
- PHASE1
LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML)
- Status
- TERMINATED
- Phase
- PHASE4
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
- Status
- COMPLETED
- Phase
- PHASE2/PHASE3
Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
- Status
- COMPLETED
- Phase
- PHASE1
Lenalidomide Therapy In Previously Untreated, Advanced Stage Follicular Lymphoma
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
Lenalidomide and Prednisone in Low and Int-1 Myelodysplastic Syndrome (MDS) Non 5q MDS
- Status
- COMPLETED
- Phase
- PHASE2
Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE2
Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1